Top Back to top

Post-transplantation cyclophosphamide-based after HLA-matched versus haploidentical donor transplants in patients with Hodgkin lymphoma: a comparative study of the LWP EBMT

Lymphoma Working Party (LWP)
Study type:
Study number:
Type of Stem Cell Treatment:
Allogeneic - Haploidentical
Non-Hodgkin’s Lymphoma (NHL)
Short title:
PTCy from MSD, MUD or Haplo for HL
Primary objective:
The use of post-transplant cyclophosphamide (PTCy) is highly effective in preventing graft-versus-host disease (GVHD) in the haploidentical (Haplo) transplant setting and is being increasingly used in matched sibling (MSD) and matched unrelated (MUD) transplants [1-7].

As a consequence, PTCy has contributed to the wider use of haploidentical donors in patients with relapsed/refractory Hodgkin's lymphoma [8,9], allowing to find a donor for the majority of patients. For this reason, there has been significant interest in comparing the outcome between haplo with PTCy versus MSD an MUD without PTCy [10], with similar results in both groups.

However, there is no information on the impact of donor types in patients with HL undergoing allogenic hematopoietic stem cell transplant using homogeneous GVHD prophylaxis with PTCy.
Key inclusion criteria:
o First allogeneic stem cell transplantation or first allogeneic stem cell transplantation as salvage therapy for HL who developed disease recurrence after autologous stem cell transplantation.
o Stem cell source: peripheral blood or bone marrow
o Conditioning regimen: MAC and RIC
o GVHD prophylaxis: PTCy +/- other immunosuppressants
All EBMT member countries
Principal investigator:
Dr. Juan Montoro
EBMT Study coordinator:
Hervé Finel
Reason for processing personal data:
Patients’ data is needed to be able to identify the patient and calculate age at any time (impact on SAEs and response to clinical medications). Health care personal data is part of the CV collected for evidence of proper qualification for running the trial.
Categories of personal data collected:
Medical data already reported to the EBMT Registry
Recipients who may access the data:
Paris Study Unit
3rd-party processors of Personal Data on behalf of EBMT/Service provider:

Privacy notices

Article 6 lawful basis for processing personal data:
Article 6.1 (a) - Consent (Collection)
Article 9 basis for processing special category data:
Article 9(2) (a) - Consent (Collection)

Data Protection Impact Assessments

Rights available to individuals:
Data portability
Is a Data Protection Impact Assessment required?:
DPIA performed for EBMT Registry (WP & NIS Studies)
Retention Schedule (if possible):
at least 5 years after the final report or first publication of study results